Objectives: To describe the epidemiology and susceptibility of pathogens (including ESBL producers) from hospital-acquired (HA) versus community-acquired (CA) urinary tract infections (UTIs) and ICU-versus non-ICUassociated intra-abdominal infections (IAIs) in Turkey as a part of the SMART study.
Introduction
The Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Citrobacter spp. and Enterobacter spp., is the family most commonly implicated in the aetiology of both urinary tract infections (UTIs) and intraabdominal infections (IAIs). [1] [2] [3] Over the last decade, a dramatic increase has occurred in the worldwide prevalence of ESBL-positive Enterobacteriaceae, which frequently show resistance to several antibiotic classes, including fluoroquinolones and aminoglycosides, [4] [5] [6] and thus represent a challenge for practitioners, further limiting antibiotic therapy choices and adversely impacting patient outcomes. [6] [7] [8] The choice of empirical antimicrobial therapy is guided by knowledge of the bacterial spectrum and the extent of antimicrobial resistance. 9, 10 Given the global increase in antimicrobial resistance, particularly for Gram-negative bacteria, the variability in antimicrobial resistance in different geographical regions and over time, and the paucity of novel antibiotics in development, continuous surveillance of the pathogen prevalence including the prevalence of ESBL producers, as well as of the emergence and trends of antimicrobial resistance, has been considered essential for guiding effective empirical therapy. 3, 7, 11 The Study for Monitoring Antimicrobial Resistance Trends (SMART) is an ongoing global surveillance programme that has monitored the susceptibilities of Gram-negative bacilli from IAIs since 2002 and the susceptibilities of Gram-negative bacilli from hospitalized patients with UTIs since late 2009. 3 This report describes the epidemiology and susceptibility of pathogens (including ESBL producers) from hospital-acquired (HA) versus community-acquired (CA) UTIs and ICU-versus non-ICUassociated IAIs in Turkey in 2011-12 as a part of the SMART programme.
Materials and methods
For this report, 363 Gram-negative pathogens from HA and CA UTIs and 458 Gram-negative pathogens from patients with IAIs in the ICU and non-ICU wards were collected in 2011 and 2012 at six hospitals in Turkey. Participating sites each collected up to 50 consecutive, non-selected aerobic or facultative Gram-negative pathogens from UTIs and up to 100 aerobic and facultative Gram-negative pathogens from the IAIs. Only one isolate per species per patient was accepted into the study.
HA versus CA UTIs and ICU-versus non-ICU-associated IAIs were compared in terms of the distribution of species isolated, percentage of phenotypically ESBL-positive isolates by species and the susceptibility for Gram-negative isolates overall and individual species.
A UTI was defined as HA or CA if cultured 48 h or ,48 h postadmission, respectively. Isolates were identified to the species level and sent to a central lab [International Health Management Associates (IHMA), Inc., Schaumburg, IL, USA] for susceptibility testing and confirmation of identification. Organism collection, transport, confirmation of organism identification, susceptibility testing and the development and management of a centralized database were co-ordinated by IHMA, Inc. MICs were determined by the CLSI-recommended broth microdilution testing method using custom MicroScan panels (Beckman Coulter Inc.). 12 MIC interpretive criteria followed published guidelines of the CLSI. 13 E. coli, K. pneumoniae, K. oxytoca and P. mirabilis isolates were classified phenotypically as ESBL producers if there was at least an 8-fold reduction of MIC for ceftazidime or cefotaxime tested in combination with clavulanic acid versus their MICs when tested alone. 13 Quality controls were performed on each day of testing using appropriate ATCC control strains, following CLSI and manufacturer guidelines. Results were included in the analysis only when corresponding quality control results were within the acceptable ranges. 13 
Molecular characterization
Per SMART protocol, all ertapenem-non-susceptible Enterobacteriaceae and a random selection of about half of phenotypically ESBL-positive E. coli, K. pneumoniae, K. oxytoca and P. mirabilis isolates were molecularly characterized for b-lactamase genes. Genes encoding ESBLs (TEM, SHV, CTX-M, VEB, PER, GES), carbapenemases (KPC, NDM, IMP, VIM, OXA-48-like) and AmpC b-lactamases (CMY, DHA, FOX, MOX, ACC, MIR, ACT) were detected using a combination of microarray (Check-MDR CT101; Check-Points B.V.) and multiplex PCR assays as described previously. 14, 15 Detected genes were sequenced and compared with the content of public databases. Carbapenemases were only detected among the ertapenem-nonsusceptible isolates.
Ethics
The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the Karadeniz Technical University Medical Faculty Ethics Committee (24237859-462; 15 July 2015).
Statistical analysis
Data are expressed as number (n) and percentage (%). v 2 test was used for comparisons. P , 0.05 was considered as the level of statistical significance.
Results

Distribution of species isolated in UTIs and IAIs
HA UTIs were caused by 14 species (40.2% E. coli; 22.5% K. pneumoniae; 10.0% Pseudomonas aeruginosa), while 9 species were found in CA UTIs (73.9% E coli; 13.0% K. pneumoniae; 4.3% K. oxytoca). E. coli isolates were significantly more common in CA than HA UTIs (73.9% versus 40.2%, respectively; P , 0.001), whereas P. aeruginosa (10.0% versus 2.2%; P " 0.017), Acinetobacter baumannii (5.9% versus 0%; P " 0.017) and Serratia marcescens (5.2% versus 0%; P " 0.026) were more common in HA than CA UTIs ( Table 1) .
The three most common species for ICU-associated IAIs were E. coli (25.8%), A. baumannii (23.7%) and K. pneumoniae (14.0%), and for the non-ICU-associated IAIs were E. coli (43.3%), P. aeruginosa (14.0%) and K. pneumoniae (13.2%). E. coli was significantly more common in non-ICU-associated IAIs (P " 0.003), whereas A. baumannii was more common in ICU-associated IAIs (P , 0.001) ( Table 1 ).
Phenotypic ESBL rates for Gram-negative isolates
The rates for ESBL-positive E. coli were higher in HA than CA UTIs (50.5% versus 38.2%; P , 0.001) as well as in non-ICU-than ICUassociated IAIs (52.5% versus 29.2%; P " 0.029), while the rates for ESBL-positive K. pneumoniae were similar between the two types of UTI (44.3% versus 41.7% in HA and CA UTIs, respectively) and IAI (53.8% versus 39.6% in ICU and non-ICU wards, respectively) (Tables 2 and 3 ).
Susceptibility for Gram-negative isolates
For UTIs, susceptibility was lower in HA than in CA for the majority of the drugs studied. Of the drugs studied, only amikacin was active against 90% of both HA and CA pathogens when all Gramnegative pathogens were combined, and ertapenem, imipenem and cefoxitin were active against 90% of CA pathogens (Table 2 and Figure 1 ).
For IAIs, the susceptibility of E. coli was generally lower in non-ICU wards, while the reverse was true for K. pneumoniae, A. baumannii and P. aeruginosa with a lower susceptibility to antibiotics generally in ICU wards. Susceptibility of A. baumannii to imipenem and amikacin was remarkably low in ICU wards (18.2% and 22.3%, respectively), while P. aeruginosa was associated with 20% lower imipenem and amikacin susceptibility and 40% lower ciprofloxacin and levofloxacin susceptibility in ICU than in non-ICU wards (Table 3 and Figure 2 ).
Carbapenemase content of Enterobacteriaceae
The prevalence of detected carbapenemases among all Enterobacteriaceae was significantly different (P " 0.03) between Urinary tract infections and intra-abdominal infections in Turkey JAC HA and CA UTIs, with 12 carbapenemase-positive isolates among the 226 HA UTI Enterobacteriaceae isolates (5.3%) versus 0 of 90 CA UTI isolates. The 12 carbapenemase-positive UTI isolates comprised 10 K. pneumoniae isolates, 1 E. coli isolate and 1 Enterobacter cloacae isolate. All 12 isolates carried an OXA-48-like carbapenemase, with 1 isolate co-carrying a VIM-31 gene and 3 isolates co-carrying ESBLs. Among Enterobacteriaceae isolates from the IAIs, there was no significant difference (P " 0.92) between the rate of carbapenemase-positive isolates from the ICU and non-ICU wards, with 3.4% (2 of 58 isolates) and 3.2% (9 of 282 isolates) carbapenemase-positive isolates, respectively. The 11 carbapenemase-positive IAI isolates comprised 7 K. pneumoniae and 4 E. coli isolates. All 11 isolates carried an OXA-48-like carbapenemase with 3 isolates co-carrying an ESBL.
Discussion
Our findings based on the evaluation of Gram-negative pathogens from UTIs and IAIs from six hospitals in Turkey in 2011-12 revealed E. coli as the most common pathogen, followed by K. pneumoniae in UTIs and non-ICU-associated IAIs, and A. baumannii in ICU-associated IAIs. HA UTIs were associated with a lower prevalence of E. coli and a higher prevalence of P. aeruginosa and ESBL-positive E. coli, along with a lower susceptibility to Susceptibility of all Gram-negative species combined is shown using breakpoints appropriate for each species (0% susceptible assumed for species with no breakpoints for any given drug). Susceptibility values 90% are shown in bold and differences 10% between HA and CA isolates are underlined. *P , 0.001 compared with CA UTIs. Koksal et al. Urinary tract infections and intra-abdominal infections in Turkey JAC the studied antibiotics. Considering IAIs, a higher prevalence of E. coli and higher rates of ESBL-positive E. coli along with the lower susceptibility of E. coli to the studied antibiotics were noted in non-ICU wards, whereas higher prevalence of A. baumannii and lower susceptibility of K. pneumoniae and P. aeruginosa were noted in the ICU wards. A very low susceptibility of A. baumannii was noted to all antibiotics in IAIs, and to imipenem and amikacin, in particular, in ICU wards. Overall, HA UTIs and ICU-associated IAIs were associated with a lower susceptibility to antibiotics. In general, amikacin, ertapenem, imipenem and cefoxitin were the most active agents in these settings.
Isolated species UTIs
The analysis of global isolates from UTIs (n " 24 705) from the 2009-11 SMART revealed E. coli (47.8%) to be the most frequently isolated species, followed by K. pneumoniae (14.5%) and P. aeruginosa (9.4%). 16 Likewise, in the current study the two most common species in both CA and HA UTIs were E. coli (40.2% and 73.9%, respectively) and K. pneumoniae (22.5% and 13.0%, respectively). Compared with CA UTIs, HA UTIs were caused by a greater variety of species, by a significantly smaller proportion of E. coli and a significantly larger proportion of P. aeruginosa, A. baumannii and S. marcescens.
IAIs
Data from the 2002-11 SMART studies conducted worldwide revealed that E. coli was the most common organism isolated from patients with IAIs, followed by K. pneumoniae and P. aeruginosa.
10,11,16-21 E. coli, P. aeruginosa, K. pneumoniae and A. baumannii were the four most common species isolated in IAIs in Turkey. The distribution of species differed between settings, with higher rates for E. coli in non-ICU wards and for A. baumannii in the ICUs. The prevalence of A. baumannii was also found to be high in the Middle East region compared with other regions in a recent SMART study, and a higher prevalence of A. baumannii was reported in the ICU than non-ICU wards in almost all studied geographical regions. 22 Additionally, ICU stays have been reported to represent a risk factor for acquisition of A. baumannii infections. 23 
ESBL rates UTIs
The increasing prevalence of ESBL-positive Enterobacteriaceae and the emergence of carbapenemase-producing isolates has been well-documented to be associated with increasing antimicrobial resistance in UTI pathogens from hospitalized patients. 24 The rate of ESBL-positive E. coli (50% versus 38%) was much higher in HA than CA UTIs in Turkey, while the rates for ESBL-positive K. pneumoniae (44% versus 42%) were similar regardless of the type of acquisition. These rates seem to be higher than those reported in previous SMART analyses in most global regions, ranging from 8.5% to 17.9% for E. coli and 8.8% to 38.9% for K. pneumoniae.
14,25
Considering isolates from a variety of infection sources, high EBSL rates in Turkey were also reported in other studies, including the Tigecycline Evaluation and Surveillance Trial 26 on antimicrobial IAIs ESBL production has been increasingly recognized worldwide among Enterobacteriaceae strains. 11 Worldwide data from previous SMART analyses revealed regional differences in ESBL production rates for both E. coli (1.2%-64.9%) and K. pneumoniae (9.5%-46.8%), and a steady increase in ESBL production rates over time. 11, 16, 17, 21, [28] [29] [30] Rates for both ESBL-positive E. coli (52.5% in non-ICU, 29.2% in ICU) and K. pneumoniae (39.6% in non-ICU, 53.8% in ICU) strains were higher in Turkey compared with the 2005-07 global, 2009-10 global and 2002-11 European SMART rates described elsewhere, 17, 28, 29 and more consistent with regions with particularly high ESBL rates such as Asia, Latin America and the Middle East. 10, 16, 21, 30 Rates for ESBL-positive isolates also differed by setting in our study; similarly to other reports in the literature, ESBL-positive K. pneumoniae appeared more commonly in ICUs. 7 Accordingly, the susceptibility of K. pneumoniae was generally lower in ICU wards in the present study. On the other hand, ESBL-positive E. coli was less common in ICU wards in the current study, but the sample size was small.
Carbapenemase producers were detected among both UTI and IAI isolates, and all isolates carried OXA-48-like genes with one isolate co-carrying a VIM gene. This finding is consistent with reports describing a substantial increase in prevalence of OXA-48 producers in Turkey since the beginning of 2010s. 31 The geographical epicentre of Enterobacteriaceae carrying VIM enzymes is reported to be in nearby Greece. 31 
Susceptibility UTIs
Susceptibility was almost always lower in HA UTIs than in CA UTIs in our study, even for K. pneumoniae for which the ESBL rates were similar in CA and HA infections. This was at least partly due to the carbapenemase-positive Enterobacteriaceae detected in isolates from HA UTIs, with almost all of them detected among K. pneumoniae.
Previous SMART studies revealed that ertapenem and imipenem were highly active against ESBL-producing strains of E. coli, 3, 14, 25 while these agents appeared less active against HA than CA isolates for ESBL-producing strains of K. pneumoniae. Similarly, our findings revealed the high activity of ertapenem and imipenem against both E. coli and K. pneumoniae from CA UTIs, while slightly lower activity against K. pneumoniae was noted in the HA UTIs.
Hence, our findings support that E. coli and K. pneumoniae continue to be the principal pathogens of CA and HA UTIs and that the carbapenems and amikacin maintain a high level of activity against a wide range of Enterobacteriaceae with slightly higher resistance rates in HA UTIs caused by K. pneumoniae.
3,14
Our findings are also consistent with data from the 2009-11 SMART programme in the USA 3 and the 2009-10 SMART programme in North America and Europe 14 in terms of resistance of Enterobacteriaceae to the fluoroquinolones ciprofloxacin and levofloxacin, as well as widespread resistance to ampicillin/sulbactam in UTIs. Low susceptibility to these agents and to cephalosporins, due in large part to high ESBL rates among E. coli and K. pneumoniae, have reduced therapeutic options for empirical UTI therapy to a limited list of drugs in Turkey, particularly in HA infections.
IAIs
Overall in Turkey, the susceptibility of the two most prevalent IAI pathogens (E. coli and K. pneumoniae) was low, with only ertapenem, imipenem and amikacin inhibiting 90% of E. coli, and imipenem, amikacin and cefoxitin inhibiting 90% of K. pneumoniae responsible for IAIs.
This seems consistent with data from previous SMART analyses that revealed continued efficacy of amikacin, ertapenem and imipenem against Gram-negative bacilli from patients with IAIs. 10, 17, 21, 32 Analysis of global trend data from 2002 to 2007 from the SMART study on IAIs revealed lower susceptibility of E. coli from HA than CA infections for all antimicrobial agents, apart from carbapenems. 33 Our findings related to lower susceptibility of E. coli in non-ICU than ICU wards should be interpreted with some caution because the sample size for ICU isolates was relatively small.
Our findings revealed very low susceptibility rates for imipenem against A. baumannii (18.2% in ICU wards, 41.9% in non-ICU wards) and P. aeruginosa (36.4% in ICU wards, 54.9% in non-ICU wards) from IAIs, particularly in ICU wards. A decline in susceptibility among P. aeruginosa and Acinetobacter spp. to imipenem was reported in the 2003-10 SMART programme on nonEnterobacteriaceae isolates from patients with IAIs in the AsiaPacific region, particularly for HA pathogens. 34 In the 2010 data from the Comparative Activity of Carbapenem Testing (COMPACT) II study, 29.8% of P. aeruginosa and 73.0% of A. baumannii isolates were reported to be non-susceptible to at least one carbapenem. 35 Notably, longitudinal data from the SENTRY Antimicrobial Surveillance Program revealed a significant increase in carbapenemresistance rates among A. baumannii isolates collected in two Turkish medical centres during the 2000-06 period (20%-60%), largely driven by the dissemination of clones producing OXA-type carbapenemases. 36 In addition, Turkish data from the COMPACT study on the analysis of in vitro activities of carbapenems against clinical Gram-negative isolates obtained from ICU and non-ICU patients in 2008 revealed that, of 596 isolates, 188 (31.5%) were resistant to at least one of the carbapenems. 37 Decreased activity of cephalosporins and quinolones with susceptibilities ranging from 50.0% to 88.5% against Gram-negative bacilli from patients with IAIs has been indicated to be an everincreasing problem in previous SMART analyses, and is mirrored in the current study. 14, 17, 21, 32, 38 Data on levofloxacin and ciprofloxacin activity against A. baumannii (11.7% and 25.0% susceptible, respectively) in IAIs overall, and that of fluoroquinolones against P. aeruginosa (84.7% for both agents overall) particularly in non-ICU wards (92.2% for both agents) in our study are consistent with Urinary tract infections and intra-abdominal infections in Turkey JAC a higher susceptibility to fluoroquinolones among P. aeruginosa (70%-80%) 4, 34 than Acinetobacter spp. (,30%) 4 reported by previous US (2007-08) 4 and Asia-Pacific region (2003-10) 34 SMART analyses. When data from Turkey are compared with US (2007-08) 4 and Asia-Pacific region (2003-10) 34 SMART data, susceptibility of Gram-negative bacteria to fluoroquinolones in IAIs seems to be similar for E. coli, but slightly higher for K. pneumoniae and P. aeruginosa, particularly in non-ICU wards, and much lower for A. baumannii regardless of the ward type.
It should be noted that owing to the concerns of increasing resistance not only to fluoroquinolones but also to other antibiotics, fluoroquinolones have been recommended to be prescribed prudently and be restricted only to regions with 90% susceptibility rates. 11, 39 Based on our findings indicating high rates of resistance to cephalosporins, fluoroquinolones and b-lactam/b-lactam inhibitor combinations exhibited by the four studied IAI species, particularly by A. baumannii with very low susceptibility even to imipenem, therapeutic options for empirical treatment of IAIs are limited in Turkey. This is apparent particularly in ICUs where A. baumannii infections are more common and the susceptibility of K. pneumoniae, P. aeruginosa and A. baumannii is generally lower than in non-ICU wards.
Turkey is currently the highest antibiotic consumer within the European region with 42.3 daily doses/1000 inhabitants per day (DID). Thus, the Turkish government has published a 'Rational Drug Use National Action Plan 2013-2017' with quantitative targets to reduce antibiotic use (by 2 DID annually between 2014 and 2017) and antimicrobial resistance. 40 In this regard, our findings provide baseline data on antibiotic resistance as well as guidance on rational drug use and antimicrobial stewardship programmes in Turkey. Surveillance studies such as SMART can and indeed have been used to inform guidelines for the treatment of infections, such as the SIS/IDSA guidelines for the diagnosis and management of complicated IAIs, 41, 42 and continued surveillance in Turkey could be used to measure the impact of any interventions to reduce antibiotic use and antimicrobial resistance.
Certain limitations to this study should be considered. First, our sample sizes are small for some subsets of the data (resulting in large confidence intervals) and our findings lack documentation of trends of susceptibility patterns of Enterobacteriaceae, complete regional coverage and characterization of a full complement of antimicrobial agents. Second, lack of data on comparison of the activity of the different antimicrobials against ESBL-positive isolates seems to be another important limitation of the study. Nevertheless, our findings provide data on appropriateness of antimicrobial therapies to be confidently selected for evidence-based treatment of Gram-negative UTIs and IAIs in Turkish settings.
Conclusions
The present report on 2011-12 SMART data from Turkey demonstrates that E. coli continues to be the principal pathogen of UTIs and IAIs in Turkey and rates of ESBL-positive isolates and antimicrobial resistance among Gram-negative bacilli from both UTIs and IAIs are high, particularly for HA UTIs and ICU-associated IAIs. High ESBL rates among E. coli and K. pneumoniae, low susceptibility to fluoroquinolones and high rates of resistance exhibited by A. baumannii to most antimicrobial agents including imipenem in IAIs, mean that therapeutic options for empirical UTI and IAI therapy, particularly in HA UTIs and ICU-associated IAIs, are diminishing to a limited list of drugs in Turkey. Further monitoring of regional surveillance regarding the epidemiology and antimicrobial susceptibility profiles is needed to guide empirical antimicrobial therapy for UTIs and IAIs.
